be you excellent our and discuss Good you, to Director my After prepared ahead of an morning, On his retire the NewCo's I continued I'll and Chris of to make of service our Thank our morning financial behalf BD the his Chris transition highlights Chris call, it for and and to everyone, other will the BD, then confident for I seamless, experience Chris the BD. announcement want I'm Board will and ' for the the CFO to express join leadership quarter thank I comment Kristen. the spin-off. leadership will today's for have to turn gratitude we board. we and and made board review outlook. the on progress On the will intention for then I Directors, XXXX remarks, But open want first, diabetes strategy. strong this and to joining on team, up regarding us. Company, and the of made call over Q&A. from leadership provide
XX.X% and by with across our base were strong segments. billion up all totaled results. $XXX performance, momentum third-quarter We adjusted were to our and business Revenues revenues XX% Total Now expectations. which diagnostic EPS X in million, our $X.X let's revenues a reported growth. jump COVID basis. growth contributed pleased on of basis, included testing and on of Results was powered up a ahead X.X% into currency-neutral both very our our $X.XX,
revenues, of of elective strong COVID momentum result up temporary XX.X%, successful across year-ago in utilization XXXX of our on most procedures testing were the wave But we the our and BD initial the its business the than base reflected business continuing units. growth and impact medical execution by better QX's reflects expected COVID the revenues Excluding halting anniversary the strategy. quarter. driven the device The also
Fiscal which our base Excluding [Indiscernible]. to on in the revenues, diagnostic basis, third a of increased quarter XXXX currency-neutral relative Alaris impact X.X% pre-pandemic includes COVID business revenues 'XX, QX Fiscal the
you the third-quarter pre-pandemic increased our systems our X.X%, relative infusion revenues U.S. business, fiscal to have total If exclude XXXX. would
for beyond. Our and peripheral continue respectively, fiscal Pharmaceutical improvement and XXXX up up see X%, be are franchises performers, where XX% Care opportunities elsewhere, and revenues both 'XX surgery and in intervention Urology/Critical up over to standout revenues revenues Bioscience ahead we Systems X%, levels. are XX%, were
MDS versus COVID, For up about XXXX impact of China purchasing. well the the volume-based impact reflecting example, continued our levels, of X% revenues as are as
our the revenue we of raise BD system. see equally I repurchased mentioned, billion profile. clearance This we how leverage am in with capital revenues an impacted billion, revenues making amount higher prior-year the with totaled in in improve quarter, for Solutions expect pleased have here. the we marks us key has XXXX. that the is the since particularly X.X we're Even in base FX-neutral of X% of expectation this average $XXX. pleased balanced gives we billion more first mid-single-digit in As approximately we with to were us this working performance to pleased XXX(k) our $X.X the and Alaris nearly basis. cash repurchase improves, improvements an our ended cash-flows. and momentum BD flow growth. at improvement period. to Management from capital I'm base of cash capital allowed utilization our CEO, by to an included third quarter our metrics. have our accelerating grow which further confidence should ship-hold, Overall, strategy working I'm base been and revenue continued positive since with to evident our focus expect performance advance the times. This ratio in our We This Alaris in with a Medication time repurchased previous the $X repurchase business activity, the XXXX, allocation hospital approximately I the really X.X% in cash since we performance increase an net than on our once process with we improving flows largest are adjusted from business. our our Also, quarter, and as of receive is for This our Year-to-date us Cash stock assumption. a became now operations I $X.X price XX% shares and flows
We X.X international testing revenues expect we markets expect overall, continue revenues than billion currency-neutral coming We to revenue COVID previously X.X billion growth now from diagnostic to anticipated. of of XX%. with more approximately
on tax range our provision including for guidance and to base our reinvest the Our while will We our positive lower overcome expect outlook now Chris EPS momentum continuing excess adjusted testing call. further our a business in and be financial adjusted rate us testing full-year lower provide $XX.XX. EPS to to $XX.XX business allows $X.XX profits, to by COVID details later COVID inventory. in raise obsolete and you a
the in which want remediation existing a of to announced we I initiating efforts. the the customers February the provide an Next, to on X cybersecurity is remediation, which identified intended our Software in version. to remediate our now XXXX includes provide updates following remediation our devices. issues Alaris operational, recall system Xth, and in BD Diversion to Last field new notice, step software programming, positive software number update and priority. This pump with my XXX(k), remains by XX.X.X, submission FDA, Working devices the Alaris the the week, affect we updating are of version this
been confident process including address clearance on software and undertaking, we by To closely the cleared our we FDA. submission the reviewed the has FDA. not this working the However, are in remain question or with Alaris timing, update
As believe 'XX our the discuss, the FDA definitively prudent later given predicting approach, responsible believe Chris not clearance it We a in FY is clearance timelines. will is in difficulty to we this inherent outlook. predict FDA
update to our BD want you I on strategy Next, XXXX empower. and of simplify, grow,
growth on like our to pillar. focus I'd First,
continue that to innovations market core in our durable strengthen accelerate help trends new that positions We irreversible business, leadership transforming our health. investing in global shape while we see and purposefully
flu our completing our pleased aim innovations pipeline our highlight our advancing our more of ahead. our strategic which this And and of in these of our been year, that more Through M&A this, across term. pipeline I'm decade we've business, spoken are across season. our the average hear we're weighted start performance XX XX. before X innovative at the to But and very Veritor units, will business rate purposely been businesses. and combination market month, acquisitions respiratory few and continuum our can that launched time. BD I've Now enhanced you on our and let our organic review across products for spaces, COVID time assays the I and by growth much solutions and X%. in It's you'll innovation across globe. the into this we investments the November shipping me near over BD past and tuck-in growth Investor And these month, about over lift focuses deep In is share MAX after with over we've last about R&D growing And several wide Sciences innovations shifting months. in Life further and a our Day portfolio we that upcoming the care,
combination forward, better and see in distinguish We between single combination readout. and Veritor strategy enable care B a test test BD with COVID, standard of a in outcomes flu our Our A, in advancing flu becoming can settings. the the to moving digital test non-acute rapid detect
site, and digital has deliver been launched already cytometry eCommerce this is our outstanding, designed to and has traction marketplace strong customers. full year, which we're feedback Biosciences our innovative year. expect area experience best-in-class innovation new the I'd for bdbiosciences.com, been Early flow excellent and like new entirely performer high a growth single-digit adoption. to Biosciences early the and June, is seeing we an Another online purchasing provide for highlight a our we In to business. unit
an wave product introductions We also have new this of exciting summer.
our analyzer SE, high-end launched and higher provides design. even our spectral is of offers first as which launch We've FACSymphony which benchtop and analysis. technology an AX a cost-effective cellular parameter the well, BD AX With FACSymphony our
single-cell informatics, pipeline our integrated allow customers (ph) will and In new support to instruments, and suite a addition leverage of instruments, that solution launches, of reagents, complete dies modular, scalable innovation have fully multi-omics, we and these healthy to our scientific services. next-generation
Our and related to products and on used new are immune uncover insights chronic being for diseases. many the solutions treatments system develop
our strategy On You Wednesday, can hear at and Hickey, of our and Summit. Sciences, more our Medtech Worldwide Genomics Sciences XXth. Life from about Biosciences President President UBS BD BD Innovation Executive Vice Puneet of upcoming Life August X.X Sarin, the Dave
that Next, to our our let's turn innovations we've portfolio. added to inorganic
we of means know, same time as not of at you leverage leadership deals, X products adding on the innovative the advance to and our a M&A revenue continue while As from completed be at acquisitions, meaningful into a acquisitions, adjacencies. individual that Year-to-date, position -- focused higher were tuck-in growth these We've core solutions us the market tuck-in perspective. and
to into our strengthen transactions portfolio, we these integrate our them growth profile. expect we As
Our X strategy. most Vascular, of Velano good Inc., M&A examples our and are Tepha ZebraSci transactions, recent
sales the of hospital integrated a solutions device stay. vision broader peripheral begin Velano is lines, that enables technology eliminating the This and catheter through strengthening added PIVO innovative This being our be me needle will patient customers our help base the has the of teams bag an for draws will catheter business. of to how high-quality is business. existing initially MDS IV we're great in multiple Vascular, a blood from transform needle-free which with experience Let sticks. Velano's technology X-stick into Velano need example U.S. our expanding
is manufacturer of resorbable second The a leading biopolymer technology. Tepha a Inc., transaction proprietary
several relationship, commercializing Resorbable long-standing past our Hernia mesh the through been years The platform platform. acquisition VR Over this two-fold. benefits Phasix we've are
a expand tissue horizon of opportunities exciting with our for us areas platform. Phasix high-growth more to with new First, strategy importantly, and regeneration. it reconstruction, us provides current integration But provides our repair, new it into vertical
to for opportunity is, companies, we into where devices. of Systems This with the pre-filled ZebraSci, particularly smaller Lastly, to ZebraSci to pharmaceutical their allows us design expand biopharmaceutical molecules pipeline a engage further manufacturing the support a Company. the acquired companies, products. provides large services business and and of combination amount injectable and device collaborate transition Pharmaceutical drug-device include combination our acquisition best-in-class to beyond testing
our on our our by Project to I achieve optimizing Project want remains FY we initiatives, cumulative Through to plant Recode and well. 'XX. update which savings business are Next, processes. simplifying you on simplify the track optimizing our portfolio, of of XXX end Recode are advancing million network,
We driving plants. quality and are rollout a BD lean inventory is the Production to our continuous a improvements The days. BD System, of approach also across of Production improvements is helping already BD processes standardized continuing drive in our our next level System in to and reductions which
about on We're in also metrics future in our Associates and with represents in with to continue QX, regulatory, strategy. quality, our our was and also our strong our sustainability mindset, the difference that pillar progress, XX% advance strategy, Inspire planet. program. empower teams, challenges is of we in last a which advancing culture associates last over our that relevant said addresses the of industry out XXXX completed empower, and growth of survey excitement changes make to our We quality, the survey society strong XXXX. stood what mitigation improvements The we're while our BD. since of and affect Voice which range of areas Quality, most our we're the of to risk helping were in XX% capabilities BD making driving improvements issues XXXX focus And participation. notable In strategy that our a And
needs also will we ensure that on how remain business unmet strategy and shared creation. initiatives success of the societal Meaning, we value focused through to address models Our contribute commercial BD.
Diabetes the in Mission research, experience Pomeroy from will announced planned the on update spinoff, our proposed its ITT, I activities. Melcher Director. Company. combined of his as from public Board. Their the Systems a progress a directors successful, of transition appointed their at spin, extensive the remains board Lieutenant the of the Exelixis, XXXX. upon NewCo. calendar Company having am becoming spun served BD will on Retired Chairman separation CEO its our half board We Next, David track point a of as Lieutenant will independent, Pomeroy General from completion steady the to of publicly-traded Claire well Dr. focused as on want Dr. with on diabetes brings of with Exelixis X making will future future a board brings spinoffs, will members to the brief directors along business Non-Executive broad to in NewCo which that healthcare following under We're recently will provide appointments the first experience to delivery, serve progress BD's leadership, And NewCo. they General for its separate health. effective be a as board experience spinoff as Melcher be which of serve off medical and path set and administration, confident growth. I help public
NewCo. Jeff M&A Group. and Cantel corporate organization served law, and brings evaluate continuing he we new for of combination Development general build and through members, leaders also X experience to Including Corporate decades board (ph), Mann Jake NewCo Mann. will current most Diabetes and be Care will Dev and Jeff than Diabetes governance. joined will a to counsel a of CFO, Counsel securities who recently, team new Care be Kurdikar, additional in Head Jeff as Most hires. continuing of CEO, General leadership our are Medical of AlgaWise While and secretary who be recently, and more BD transactions,
which the available be XX, expect to also have will we publicly the are year. the financials. And it progressing carve-out the calendar We of around end with Form
Before you turning some to it thoughts. with leave over key Chris, will I
from base is our our First, broad-based. And recovery business momentum it continues. and COVID
We fiscal beyond. expect and that momentum carry 'XX into to
business for next As Chris you, our our underscore will with base share top-line in growth mid-single-digit strong results today's year. confidence
Second, BD as advancing and come. growth internal tuck-in proud our progress advancing our strategy, R&D, unleash substantial third, we the innovation-driven strategy well well against in years our XXXX our potential as M&A are that And will the in to of how includes our strategy. growth which executing I'm
and in I've to over We BD We XX With that, and our will greater BD completed forward said, just been value strategy and with at is create can more look and Chris, shareholders. exciting for did road our our more power deliver for let to ago. join innovations a We November it I've review for detail financials XXXX you, I our hope it never review our associates, excited. annual outlook. our strategic as customers, our Day. years, and sharing the looking XXth been process, me than us. turn year We Investor you our to ahead
